Nectar Lifesciences Quarterly Results for Trading Insights
In Mar 2026, Nectar Lifesciences (NECLIFE) reported revenue ₹6 Cr and net profit ₹-68 Cr. Also explore NECLIFE share price charts to track price trends across different timeframes.
NECLIFE Quarterly Results — Revenue, Profit & EPS Highlights
Nectar Lifesciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Nectar Lifesciences share price chart.
- Revenue of ₹6 Cr in Mar 2026
- Net Profit of ₹-68 Cr in Mar 2026 (+61.4% vs Sept 2025, +47.7% vs Mar 2025)
- EBITDA of ₹-83 Cr in Mar 2026 (+52.8% vs Sept 2025)
- Earnings Per Share of ₹-3.38 in Mar 2026 (+56.9% vs Sept 2025)
Nectar Lifesciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
NECLIFE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 6 | 0 | 0 | 6 | 36 | - | - |
| Net Profit (₹ Cr) | -68 | -176 | -130 | -63 | 14 | - | - |
| EBITDA (₹ Cr) | -83 | -176 | -130 | -63 | 34 | - | - |
| EPS (₹) | -3.38 | -7.85 | -5.80 | -2.82 | 0.64 | - | - |
| Operating Margin (%) | 0.0% | 0.0% | 0.0% | -1212.0% | 0.0% | - | - |
NECLIFE Share Price Trend — 1-Year Movement Across Quarterly Results
Nectar Lifesciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with NECLIFE fair value estimate to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
NECLIFE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Nectar Lifesciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,069.70 Cr | 1862.8 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 164.8 |
|
Divis Laboratories
Mar 2026 |
₹180,186.80 Cr | 6713.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 237.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹152,449.36 Cr | 4516.2 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 392.4 |
|
Cipla
Mar 2026 |
₹116,150.78 Cr | 1440.1 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 209.6 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,873.98 Cr | 1350.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 509.6 |
All amounts in ₹ Crores